Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
@Bio Waarom ga je niet in op het foutenlijste van Sanderus?
Op verzoek van Rotel74 ook even op dit draadje mijn eerdere post: Discussies van de afgelopen dagen op dit forum overziende, vermeld ik toch nog maar even 1 keer opnieuw de duidelijke, zeer zelfverzekerde en trotse uitspraken van de CEO Eduardo Bravo van Tigenix: “De grote verwezenlijkingen die we onlangs hebben bekendgemaakt, zijn uiterst belangrijke stappen die ons zullen helpen om ons potentieel volledig te benutten. Ze zullen een geweldige invloed hebben op de onderneming en haar toekomst”, zo zegt Eduardo Bravo, CEO van TiGenix. “We hebben de volledige commerciële rechten voor Cx601 met positieve fase III-gegevens en zijn klaar om een markttoelatingsaanvraag in te dienen in Europa. Bovendien beschikken we over een duidelijk Cx601-traject in de Verenigde Staten met goedkeuring van de FDA voor de aanvraag. Het gaat om een potentiële markt van 2 miljard euro. We hebben onlangs Coretherapix overgenomen,een onderneming met een platform van hartstamcellen. Het voornaamste product van Coretherapix,AlloCSC-01 voor acuut myocardinfarct, bevindt zich in een vergevorderde fase II-klinische studie. Met Cx611 verwachten we een fase II-studie te kunnen beginnen bij ernstige sepsis, de voornaamste doodsoorzaak in ziekenhuizen in het westen. We zijn uiterst trots dat we een van de weinige ondernemingen zijn met zulke veelbelovende vooruitzichten voor de nabije toekomst.” Het moge duidelijke zijn, dat ik long Tigenix zit en dat blijf ik ook. Eerder met Galapagos heb ik me door negatieve verhalen laten verleiden (groten)deels te vroeg uit te stappen en dat gaat me hier niet gebeuren. Tigenix is goed bezig, geen "one-trick-pony", met een breed palet aan veelbelovende ontwikkelingen en op dagen van zwakte koop ik plukjes bij. Bij Tigenix kent men, na de zeer positieve onderzoeksresultaten, de eigen sterke onderhandelingspositie en laat men zich gelukkig niet verleiden door een te snelle deal met partners en werkt men liever aan een gedegen samenwerkingsverband. Dat noem ik buitengewoon verstandig.
Waarom zouden we ingaan op sanderus zijn veronderstellingen, want dat zijn het,veronderstellingen. Alle nieuws is bekend, niks meer,niks minder. Alleen moet sanderus er steeds zijn eigen negatieve draai aan geven. Van mij mag iedereen zijn mening geven en iedereen mag hem volgen en zelfs verkopen. Ik doe zelf mijn huiswerk en weet waar ik in beleg. En ja,in biotech zijn er geen zekerheden,meer risico,maar als biotechbeleggers zijn we daar natuurlijk allemaal van op de hoogte. Dat mes snijdt aan weerszijden . Bij goed nieuws,mooie winst,bij slecht nieuws, ....
Nice guy schreef op 6 november 2015 10:39 :
[...]
blijft natuurlijk wel opvallend dat je jezelf alleen laat zien als het aandeel daalt, afgelopen weken niet gehoord en sinds deze week weer actief met de slecht nieuws show
Dan let je niet goed op, ik heb met Tig ook mooie rijtjes gemaakt en toen was ik ook positief, een beetje realiteit kan geen kwaad.
Bijna 9% van de top van deze week eraf. Oei joei joei. Even niet opgelet. Kan me sterk vergissen maar de "schwung" up is er weer helemaal uit.
Natte krant schreef op 6 november 2015 17:12 :
Bijna 9% van de top van deze week eraf. Oei joei joei. Even niet opgelet.
Kan me sterk vergissen maar de "schwung" up is er weer helemaal uit.
Vandaag i.e.g. vlak gesloten. Op naar de volgende week met nieuwe "schwung" !
Sanderus had KBC nog wat te vertellen in het rapport over Tigenix? Ik zie dat KBC een koersdoel heeft gegeven van 1,50. Dat zou betekenen dat ze het positief inzien. Kan je het stukje over Tigenix, als dat er is anders hier posten?
TiGenix NV (TIG.BR) TiGenix Receives €5.4 million Grant for Development of Cx611 in Severe Sepsis Please click here for full report Company Update November 6, 2015 On November 2, 2015, Tigenix (Euronext Brussels: TIG.BR) announced a €5.4 million grant from the European Commission to support the SEPCELL project, a Phase Ib/IIa trial designed to evaluate the safety and efficacy of Cx611 for the treatment of severe sepsis secondary to severe community-acquired pneumonia (sCAP). Tigenix expects to enroll patients at clinical facilities throughout Europe, including Center Hospitalier Universitaire of Limoges, the Cliniques Universiktaires Saint-Luc in Brussels, the Hospital Clinico San Carlos of the Servicion Madrileno de Salud in Madrid, and the Academic Medical Center of the University of Amsterdam. As project leader, Tigenix receives €1.3 million of non-dilutive funds, and will be responsible for managing the remaining €4.1 million to fund the project’s clinical and research activities. Cx611 for the Treatment of Severe Sepsis. The SEPCELL project is a randomized, double-blind, placebo-controlled, Phase Ib/IIa study for Cx611 in severe sepsis secondary to sCAP. Subjects in the trial must have sCAP requiring mechanical ventilation and/or vasopressors. The trial is expected to enroll 180 patients, and will be conducted at approximately 50 centers throughout Europe. Subjects will be randomized 1:1 to receive Cx611 or placebo on days 1 and 3. All patients will also be treated with the standard of care, which generally includes antibiotics and anti-inflammatory drugs. The primary endpoint is the number of adverse events during a 90 day period. Secondary endpoints include the reduction in the duration of mechanical ventilation and/or vasopressors, improved survival, clinical cure of sCAP, and other infection-related endpoints. The trial is expected to launch in 2015. Analysts Jerry Isaacson, Ph.D. (AC) (646) 597-6991jisaacson@lifescicapital.com Market Data Price $1.07 Market Cap (M) $171 EV (M) $183 Shares Outstanding (M) 168.2 Avg Daily Vol 639,571 52-week Range: $0.53 - $1.44 Cash (M) $22.7 Net Cash/Share $0.16 Annualized Cash Burn (M) $14.5 Years of Cash Left ~2.0 Debt (M) $36.4 Cash and debt are pro forma as of June 30, 2015 Currency values converted at 1 Euro to 1.09 USD Financials FY Dec 2013A 2014A 2015A EPS H1 (0.12)A (0.08)A (0.08)A H2 NA NA NA FY (0.21)A (0.11)A NA Safety and Tolerability Demonstrated in CELLULA Phase I Study. Tigenix completed a placebo-controlled, dose-ranging study of Cx611 in 32 healthy male volunteers. Subjects were exposed to lipopolysaccharides (LPS), a common model for inducing inflammation, and then randomized to receive Cx611 or placebo at a ratio of 3:1. The volunteers received 250,000, 1 million, or 4 million eASCs/kg, or placebo, via IV injection. Primary endpoints were vital signs and symptoms, laboratory measures, and functional assays of innate immunity. Results from the trial suggest that the product was safe and well tolerated. No serious adverse events were reported with any of the three doses tested. With respect to anti-inflammatory activity, no significant effect of Cx611 on the lipopolysaccharide-induced symptoms could be detected. Cx611 is an Allogeneic Stem Cell Therapy. Cx611 is a cellular product candidate developed using TiGenix’s proprietary platform of allogeneic expanded adipose-derived stem cell (eASCs). The cells have low immunogenicity, and are designed to promote systemic immuno-modulatory effects. They are readily available from liposuction procedures with yields 100-1000 times higher than bone marrow cells, and can be easily expanded in culture. Pre-clinical data has demonstrated eASCs can protect against severe sepsis by reducing pro-inflammatory and inducing anti-inflammatory cytokines. Severe sepsis remains a significant unmet medical need with an estimated 15-19 million cases worldwide each year. Expected Upcoming Milestones Q4 2015 – Commence Phase Ib/IIa study of Cx611 in severe sepsis. Q4 2015 – Finalize enrollment of AlloCSC-01 Phase I/II study in AMI. Q1 2016 – File for marketing authorization of Cx601 in Europe. Q2 2016 – 1-year follow-up results from European Phase III trial of Cx601 in complex perianal fistulas in Crohn’s disease. H2 2016 – Interim analysis of AlloCSC-01 Phase II study in AMI. H2 2016 – Complete technology transfer to Lonza to manufacture Cx601 in the US. H2 2016 – File IND for a US Phase III trial with Cx601 in complex perianal fistulas in Crohn’s disease. Q1 2017 - Initiate US Phase III trial with Cx601 in complex perianal fistulas in Crohn’s disease. H1 2017 – Expected topline data from Phase II for AlloCSC-01 in AMI. H2 2017 – Potential EMA approval and commercial launch of Cx601 for complex perianal fistulas in Crohn’s disease. 2020 – Potential FDA approval of Cx601 for complex perianal fistulas in Crohn’s disease. Risk to Investment We consider an investment in TiGenix to be a high-risk investment. The Company receives revenue from the ChondroCelect cell therapy product but this revenue is not sufficient to support ongoing operations. The Company may therefore need to rely in the future on other forms of financing that may be dilutive to existing shareholders and may subsequently decrease the valuation of the Company. While the eASC product platform contains numerous promising clinical candidates, this technology has not yet been validated by a regulatory approval. TiGenix may fail to develop and bring its pipeline products to market or find appropriate partners to help develop these products. Moreover, the Company’s future marketed products may fail to achieve expected levels of sales or may be overtaken by competing products. For more information visit www.lifescicapital.com Analyst Certification The research analyst denoted by an “AC” on the cover of this report certifies (or, where multiple research analysts are primarily responsible for this report, the research analyst denoted by an “AC” on the cover or within the document individually certifies), with respect to each security or subject company that the research analyst covers in this research, that: (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or subject companies, and (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. DISCLOSURES This research contains the views, opinions and recommendations of LifeSci Capital, LLC (“LSC”) research analysts. LSC (or an affiliate) has received compensation from the subject company for producing this research report. Additionally, LSC expects to receive or intends to seek compensation for investment banking services from the subject company in the next three months. LSC (or an affiliate) has also provided non-investment banking securities-related services, non-securities services, and other products or services other than investment banking services to the subject company and received compensation for such services within the past 12 months. LSC does not make a market in the securities of the subject company. Neither the research analyst(s), a member of the research analyst’s household, nor any individual directly involved in the preparation of this report, has a financial interest in the securities of the subject company. Neither LSC nor any of its affiliates beneficially own 1% or more of any class of common equity securities of the subject company.
Risk to Investment We consider an investment in TiGenix to be a high-risk investment. The Company receives revenue from the ChondroCelect cell therapy product but this revenue is not sufficient to support ongoing operations. The Company may therefore need to rely in the future on other forms of financing that may be dilutive to existing shareholders and may subsequently decrease the valuation of the Company. While the eASC product platform contains numerous promising clinical candidates, this technology has not yet been validated by a regulatory approval. TiGenix may fail to develop and bring its pipeline products to market or find appropriate partners to help develop these products. Moreover, the Company’s future marketed products may fail to achieve expected levels of sales or may be overtaken by competing products. Dat wisten we al, maar voor de koers op korte termijn is dit niet best :(
Wil je lager bijkopen, dat je dit oude nieuws nu zo post? Heb je vannacht wat geld op straat gevonden?
Hunter300 schreef op 9 november 2015 06:34 :
Wil je lager bijkopen, dat je dit oude nieuws nu zo post? Heb je vannacht wat geld op straat gevonden?
Alle info is openbaar. Dit is wel echte info, echter deze info lijkt u niet wel te gevallen. Iedereen wordt geacht zelfstandig tot een besluit tot koop of verkoop te komen en dan al dan niet tot aktie over te gaan. Ik vind deze reactie van weinig respect getuigen. Ben ik nu de enige die hierover zo denkt? Reageren mag altijd!
kbc Strong phase III results push Cx601 to market Tigenix is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics based on allogeneic expanded stem cells. • Tigenix develops and commercialises novel therapeutics from its proprietary platform of allogeneic (donor-derived) expanded adipose-derived stem cells, known as eASCs, for inflammatory and autoimmune diseases. • Two products from this technology platform are currently in clinical development. Cx601 is being developed for the treatment of complex perianal fistulas in Crohn’s disease patients. Last August, the product showed convincing phase III results and is heading towards EMA filing in 1Q16. Cx611 is in Phase II severe sepsis and completed a phase I/II for rheumatoid arthritis. • In 3Q15, Tigenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is in a phase II study in acute myocardial infarction (AMI) for which results are expected in 2H16. • Tigenix also developed ChondroCelect, an autologous cell therapy product for repairing knee cartilage, but poor sales prompted a licensing to Sobi in 2014. • End-June, cash funds available were € 23m, sufficient to support operations into 2H16. In 4Q13, the venture arm of Spanish Griffols became a reference shareholder (21%). • We value Tigenix at € 1.5/sh based on the prospects of Cx601 and solid news flow in the coming period, warranting a Buy rating. - See more at: beursig.nl/forum/viewtopic.php?f=4&am... STRENGTHS • Cx601 might prove to be a breakthrough for the treatment of complex perianal fistula in Crohn’s. • Proven leadership in cell therapy with several clinical-stage products and extensive clinical experience. • Strong expertise in development and manufacturing of cell-based products, including regulatory issues. • Well-filled pipeline of innovative cell products. OPPORTUNITIES • Allogeneic products could be used off-the-shelf. • Cell therapy market expected to be major growth industry, with growing interest from big pharma/medtech. • Clinical development products focus on blockbuster indications (cardiac and sepsis). • All rights on Cx601 and other products. WEAKNESSES •Immune-modulatory cell industry still in infancy. •?Regulatory and reimbursement frameworks are not yet adopted for innovative cell-based products. • Lead eASC product indicated for niche market. • Refinancing has been difficult in the past. THREATS ??New technologies from established players may increase competitive pressure. • Failure of Cx601 regulatory path would be a serious setback.
Broeit er iets? Of is het fake. io op 99ct.
ik hoop dat er iets mooi broeit :)
Timmy. schreef op 9 november 2015 09:00 :
ik hoop dat er iets mooi broeit :)
Het zijn stamcellen in een schaaltje...
denk dat er eerder een jojo uit het ei kwam
Voor de liefhebbers . Ik heb Tigenix nog 2 verduidelijkende vragen gesteld waar we veel aan (kunnen ) hebben . 1 mbt de productie van stamcellen / veiligheid -erfelijkheid / controle etc. Hoe doen ze dat ? 2 het verschil tussen de cardio ontwikkeling/product bij Celyad en het cardio product van Tigenix Hartelijk dank voor het antwoord van Tigenix /Claudia D'Augusta ( wie is ze ? tigenix.com/en/page/6/management-team ) Dear Bioscience Thanks for your emails and for your interest in TiGenix. 1 Your first request of elucidation around the regulatory environment for cell therapy products is a very legitimate one and entitles a broad experience from our regulatory experts to be properly addressed. As a matter of fact, the text posted by Charlie Boon covers the classical challenges of the manufacturing and characterization of this therapies. Some of them are relevant to autologous product, derived from the same patient, and would not apply to Cx601 (which is allogeneic or from donors). Anyway, I would say that the field in general, and definitely ourselves are very aware of them and have developed our products under those considerations. We´ve been in the working groups commenting those aspects with regulators and involved in the development of current guidelines. I want to remind you that we´ve extensively discussed these aspects with regulators by means of scientific advice, at the European medicine agency and also in the member states. Besides, Cx601 was approved in 8 countries for the ADMIRE trial including the toughest European agencies so went already to a deep scrutiny there. We indeed perform exhaustive donor selection and serology testing according to tissue and cells directives (and beyond!), control raw materials and excipients, test adventitious agents at appropriate stages of production etc. We perform genetic stability to discard any genetic problem. We can demonstrate that our manufacturing process operates under predefined conditions in a consistent and reproducible manner and that batches of predefined quality can be obtained. We have used and tested different donors in the different stages of development showing a consistent and robust manufacturing process and that products are equivalent independently of donor. 2 As per your request about “What is the different between the cardio product of Tigenix and Celyad ?” the difference is the indication and the source of the cells. We are treating patients who have undergone an AMI (Acute Myocardial Infarction) therefore in an acute setting to limit the extent of tissue damage and reduce the formation of a non-functional scar with the consequence process of ventricular remodelling. Celyad is addressing the so called Congestive Heart Failure (CHF) which is not an acute setting but addresses patients with chronic advanced symptomatic heart failure, a terminal condition. The product used by Celyad is autologous while AlloCSC-01 is allogeneic (or from donor) and can be used within few days after the stent is inserted. Therefore we are not addressing the same indication. I hope that this helps. Please do not hesitate to come back to us if you have any additional question. Have a nice week-end! Claudia
@bio Bedankt dat je dit deelt! Ik vroeg me af of je als Biotech liefhebber ook andere aandelen volgt. Ik verwacht dat er deze maand in Genfit nog wel wat beweging gaat komen.
Je kent mijn drama verhaal mbt Genfit . Uitgestapt op ca 4 euro en daarna binnen 2 jaar richting de 60 euro . Heb daar wat hoogtevrees . Zit mbt biotech in Tigenix Ablynx en MDX . Denk dat ABlynx en Tigenix op dit moment de beste papieren hebben (op dit moment 100% LT).Voor beide kan 2016 een grote doorbraak betekenen . MDX misschien ook al trek ik daar iets meer twijfel bij na alle recente ontwikkelingen MDX van LT naar MT bij mij . Uiteraard kan dit alles veranderen bij belangrijke ontwikkelingen . Iedereen zit zo gebrand op GLPG . Ik denk echter dat Ablynx voor nu een veel voordeliger alternatief is en een mooiere toekomst verwachting heeft .(mijn mening )
@bioscience: Hoe schat jij de financieringspositie in van deze aandelen? GLPG: ruime kaspositie, op zoek naar partner voor feelgood-tinib; deal waarschijnlijk nog dit jaar. ABLX: ruime kaspositie dank zij Merkel deal, doch veel ijzers in het vuur. TIG: niet zo rooskleurige kaspositie; financieringsproblemen blijven de koers parten spelen. Op zoek naar partner USA en mogelijk Nasdaq IPO. (Vandaag gelezen in de Tijd dat participatie +30% mogelijk is zonder overnameverplichting indien voortkomt door aankoop van rechten bij kapitaalsverhoging). MDX: geschrapt van mijn lijstje (wegens financieringsperikelen dacht ik). Graag verbetering en/of aanvulling aub!
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
Nextensa
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
918,72
-0,64%
EUR/USD
1,0706
-0,31%
FTSE 100
8.146,86
-0,21%
Germany40^
18.004,30
-1,43%
Gold spot
2.332,68
0,00%
NY-Nasdaq Composite
17.688,88
+0,12%
Stijgers
Dalers